Yun Jung's questions to WAVE Life Sciences Ltd (WVE) leadership • Q1 2025
Question
An analyst from Wedbush Securities questioned the rationale for splitting the AATD data release into two separate announcements (Q3 and Fall) and asked if the DMD NDA submission would include monthly dosing data.
Answer
President and CEO Dr. Paul Bolno clarified that the company will release the 200mg multi-dose AATD data as soon as it is complete because it is a material dataset, rather than hold it for the 400mg cohort data. He noted the 400mg cohort is enrolling well, so the timelines could potentially converge. For the DMD program, he confirmed the plan is to include monthly dosing data in the 2026 NDA submission to support a monthly regimen on the label at launch.